Immunovant (IMVT) Income towards Parent Company (2018 - 2026)
Immunovant (IMVT) reported Income towards Parent Company of -$147.8 million for Q1 2026, down 38.88% on a YoY basis from -$241.9 million in Q1 2025, and down 33.63% quarter-over-quarter from -$110.6 million in Q4 2025.
Immunovant (IMVT) Income towards Parent Company (2018 - 2026) Analysis & Trends
Immunovant has reported Income towards Parent Company for 9 years, with the latest figure at -$147.8 million in Q1 2026.
- For the quarter ending Q1 2026, Income towards Parent Company fell 38.88% year-over-year to -$147.8 million; the trailing twelve-month figure through Mar 2026 stood at -$505.6 million (down 22.17% YoY), and the FY2026 full-year result was -$505.6 million, down 22.17% from the prior year.
- Income towards Parent Company for Q1 2026 stood at -$147.8 million, down from -$110.6 million in the prior quarter.
- The five-year high for Income towards Parent Company was -$40.4 million in Q2 2022, with the low at -$147.8 million in Q1 2026.
- Historically, Income towards Parent Company has averaged -$84.5 million across 5 years, with a median of -$75.3 million in 2024.
- Annual changes were most pronounced in 2023 — Income towards Parent Company climbed 18.68% — and 2024, when it plunged 116.11%.
- Immunovant's Income towards Parent Company stood at -$63.2 million in 2022, then advanced by 18.68% to -$51.4 million in 2023, then sank by 116.11% to -$111.1 million in 2024, then advanced by 0.44% to -$110.6 million in 2025, then plunged by 33.63% to -$147.8 million in 2026.
- The last three Income towards Parent Company figures came in at -$147.8 million (Q1 2026), -$110.6 million (Q4 2025), and -$126.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Immunovant | 5.71 Bn | 5.71 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -147.84 Mn |
| Dec 31, 2025 | -110.64 Mn |
| Sep 30, 2025 | -126.50 Mn |
| Jun 30, 2025 | -120.61 Mn |
| Mar 31, 2025 | -106.45 Mn |
| Dec 31, 2024 | -111.12 Mn |
| Sep 30, 2024 | -109.12 Mn |
| Jun 30, 2024 | -87.15 Mn |
| Mar 31, 2024 | -75.32 Mn |
| Dec 31, 2023 | -51.42 Mn |
| Sep 30, 2023 | -58.66 Mn |
| Jun 30, 2023 | -73.94 Mn |
| Mar 31, 2023 | -59.43 Mn |
| Dec 31, 2022 | -63.23 Mn |
| Sep 30, 2022 | -47.93 Mn |
| Jun 30, 2022 | -40.37 Mn |
| Mar 31, 2022 | -47.17 Mn |
| Dec 31, 2021 | -41.39 Mn |
| Sep 30, 2021 | -37.70 Mn |
| Jun 30, 2021 | -30.47 Mn |